| Literature DB >> 19401819 |
M L Smith1, W P Fitzmaurice, T H Turpen, K E Palmer.
Abstract
In this review, we focus on the potential that tobacco mosaic virus (TMV) has as a carrier for immunogenic epitopes, and the factors that must be considered in order to bring products based on this platform to the market. Large Scale Biology Corporation developed facile and scaleable methods for manufacture of candidate peptide display vaccines based on TMV. We describe how rational design of peptide vaccines can improve the manufacturability of particular TMV products. We also discuss downstream processing and purification of the vaccine products, with particular attention to the metrics that a product must attain in order to meet criteria for regulatory approval as injectable biologics.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19401819 PMCID： PMC7122513 DOI： 10.1007/978-3-540-70868-1_2
Source DB: PubMed Journal: Curr Top Microbiol Immunol ISSN： 0070-217X Impact factor: 4.291